CYADY — Celyad Oncology SA Cashflow Statement
0.000.00%
Last trade - 00:00- $16.86m
- $12.17m
Annual cashflow statement for Celyad Oncology SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -37.4 | -28.6 | -17.2 | -26.5 | -40.9 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 8.58 | -0.749 | -10.3 | -3.08 | 13.3 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.481 | -0.609 | -2.02 | 1.43 | -1.84 |
| Change in Accounts Receivable | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -27.2 | -28.2 | -27.7 | -26.6 | -28 |
| Capital Expenditures | -1.76 | -0.622 | -0.319 | -0.393 | -0.123 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 2.37 | 9.61 | 0.476 | 0.267 | 7.33 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0.607 | 8.99 | 0.157 | -0.126 | 7.2 |
| Financing Cash Flow Items | 0.716 | 3.31 | 6.84 | 4.09 | 4.26 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 43.9 | 18.3 | 5.4 | 39.5 | 3.24 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 17.3 | -1.2 | -22.1 | 12.8 | -17.6 |